A Real-World Medisoft Audit of ILUVIEN® Treatment in patients with chronic diabetic macular edema (DME)

Trial Profile

A Real-World Medisoft Audit of ILUVIEN® Treatment in patients with chronic diabetic macular edema (DME)

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 02 Aug 2017

At a glance

  • Drugs Fluocinolone acetonide (Primary)
  • Indications Diabetic macular oedema
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 02 Aug 2017 New trial record
    • 25 Jul 2017 Results (n=305 patients, 345 eyes) published in the Alimera Sciences Media Release
    • 18 Jul 2017 According to an Alimera Sciences media release, data (n=305 patients, 345 eyes) from an ongoing audit of real-world U.K. clinical practice, published online in Eye.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top